Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Daiichi Pharmaceuticals
Patients receive intravenous DS-4152 by infusion twice weekly for 21 days, followed by 2 weeks of rest; courses may repeat. Patients undergo weekly follow-up. A punch biopsy will be obtained from patients with Kaposi's sarcoma.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
Kaposi's sarcoma plus HIV infection OR metastatic solid tumor.
Life expectancy of at least 12 weeks.
NO symptomatic AIDS-defining opportunistic infection within the past 4 weeks.
Recovered from toxicity of any prior anticancer therapy.
You may not be if
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Leukemia or lymphoma.
Current gastrointestinal bleeding by stool guaiac.
Extensive bone metastases or significant radiographic osteoporosis in patients with solid tumors.
Active heart disease such as uncontrolled angina, uncompensated congestive heart failure, or dysrhythmias requiring antiarrhythmics.
Acute intercurrent infection other than genital herpes.
Symptomatic or known central nervous system involvement (including brain metastases) unless stable and off therapy.
Concurrent Medication:
Excluded:
Other anticancer therapy.
Other investigational agents.
Patients with the following prior conditions are excluded:
History of acute or chronic gastrointestinal bleeding or inflammatory bowel disease.
History of myocardial infarction within past 6 months.
Prior Medication:
Excluded:
Anticancer therapy within the past 3 weeks (6 weeks for nitrosourea or mitomycin C).
